Royalty Pharma (RPRX) Times Interest Earned (2019 - 2026)

Royalty Pharma has reported Times Interest Earned for 8 years, with the latest figure at $2.52 in Q1 2026.

• Quarterly Times Interest Earned fell 13.97% year-over-year to $2.52 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.1 (down 31.78% YoY) and the FY2025 annual result came in at $5.07, down 11.56% from the prior year.
• Times Interest Earned slipped to $2.52 in Q1 2026 per RPRX's latest filing, from $10.21 in the prior quarter.
• Over five years, Times Interest Earned peaked at $20.96 in Q4 2023 and troughed at -$1997.3 in Q4 2024.
• A 5-year average of -$157.44 and a median of $1.31 in 2024 frame the typical range for Times Interest Earned.
• The sharpest annual moves came in 2022 and 2025: Times Interest Earned slumped 22389.86% in 2022, then surged 737.19% in 2025.
• Over 5 years, Times Interest Earned stood at -$727.99 in 2022, then jumped by 102.88% to $20.96 in 2023, then sank by 9627.47% to -$1997.3 in 2024, then jumped by 100.51% to $10.21 in 2025, then slumped by 75.33% to $2.52 in 2026.
• According to Business Quant data, Times Interest Earned over the past three periods registered $2.52, $10.21, and $5.37 for Q1 2026, Q4 2025, and Q3 2025 respectively.